Newron terminates sarizotan development in Rett syndrome
Newron Pharmaceuticals S.p.A.s Sarizotan failed to meet efficacy endpoints in the Phase III STARS study.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2152 entries already.
Entries by Thomas Gabrielczyk
Roche gets FDA okay for COVID-19 antibody test
Roche Diagnostics has received FDA Emergency use approval for its highly specific Elecsys antibody test.
European Biotechnology Guide 2020 goes digital
Additional to the print edition the European Biotechnology Science & Industry Guide 2020 is available digital in the App Store and at Google Play. Download the free BIOCOM app on smartphone, tablet or laptop and have the complete edition in one hand.
Phages as a promising alternative to antibiotics
Austrian Phagomed wants to close a Series A financing in 2020. The start-up is working on phage-based treatments as a new alternative to antibiotics.
Bone Therapeutics bags €11m
Belgian Bone Therapeutics SA has secured €11m to foster development of its late stage pipeline candidates.
Cevec launches ELEVECTA platform
Cevec Pharmaceuticals GmbH has launched a new, scalable production platform for AAV gene therapy vectors.
Artes enters COVID-19 vaccine race
German vaccine developer ARTES Biotechnology GmbH will develop a COVID-19 subunit vaccine based on virus-like particles (VLP), which include two proteins of SARS-CoV-2.
Bayer, Novartis, and Trump convicted by Nature
The politically overhyped use of old malaria drugs in combination with COVID-19-specific candidates has been demonstrated to be dangerous, reports Nature Medicine.
Drug from worms dampens autoimmune response
German researchers have isolated a substance from parasitic roundworm larvae to alleviate inflammation and treat asthma in a rodent model.
Fully digital partnering at BIO-Europe Spring 2020
BIO-Europe Spring: Leading life sciences partnering event pivots to deliver dealmaking
opportunities in a new format during very unusual times. With just 16 days to plan, EBD Group transformed BIO-Europe Spring from a physical event held in Paris to a fully digital solution where 1,700 delegates around the world participated in virtual partnering meetings and panels.